Impact of Product-Related Factors on Immunogenicity of Biotherapeutics

Cites (290)

Items 201–283 of 283

1. Five‐year follow‐up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone
   Guy Massa, M Vanderschueren‐Lodeweyckx, Roger Bouillon · 1993 · Clinical Endocrinology
2. IGIV: Contents, properties, and methods of industrial production—evolving closer to a more physiologic product
   Turf D. Martin · 2005 · International Immunopharmacology
3. Toxicity as a result of immunostimulation by biologics
   Elizabeth J Gribble, Pallavar V Sivakumar, Rafael A. Ponce, Steven D. Hughes · 2007 · Expert Opinion on Drug Metabolism & Toxicology
4. New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development
   Laura Perry, Timothy D Jones, Matthew Baker · 2008 · Drugs in R&D
5. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
   Abdul-Ahad Ak, AR Galazka, M Revel, Mauro Biffoni, Borden Ec · 1997 · PubMed
6. Acute Renal Failure After Administration of Intravenous Immunoglobulin: Review of the Literature and Case Report
   Doreen Bianchi Winward, Mary T. Brophy · 1995 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
7. Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses
   Edward T. Creagan, David L. Ahmann, Stephen Frytak, Harry J. Long, Myron N. Chang, Loretta Marie Itri · 1987 · Cancer
8. Structures of the major carbohydrates of natural human interleukin‐2
   Harald S. Conradt, Rudolf Geyer, Jürgen Hoppe, Lutz Grotjahn, Annelore Plessing, H. Mohr · 1985 · European Journal of Biochemistry
9. Exposure to Topical Bovine Thrombin During Surgery Elicits a Response Against the Xenogeneic Carbohydrate Galactose α1-3Galactose
   Jonathan G. Schoenecker, Rachel K. Hauck, Meg C. Mercer, William Parker, Jeffrey H. Lawson · 2000 · Journal of Clinical Immunology
10. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses
    Maria D.F.S. Barbosa, Esteban Celis · 2007 · Drug Discovery Today
11. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another
    Iain C. Macdougall · 2003 · Current Medical Research and Opinion
12. Evaluation of the Immuno-Stimulatory Potential of Stopper Extractables and Leachables by Using Dendritic Cells as Readout
    Robert Mueller, Anette Christine Karle, Anne B. Vogt, Harald Kropshofer, Alfred Ross, Karsten Mäder, Hanns‐Christian Mahler · 2009 · Journal of Pharmaceutical Sciences
13. Glycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins
    T. Shantha Raju · 2003
14. Epoetins: differences and their relevance to immunogenicity
    Anton Haselbeck · 2003 · Current Medical Research and Opinion
15. Clouding and Deactivation of Clear (Regular) Human Insulin: Association With Silicone Oil From Disposable Syringes?
    Richard K Bernstein · 1987 · Diabetes Care
16. Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy
    Stéphane Chenu, Anne Grégoire, Yanina N. Malykh, Athanase Visvikis, Lucía Monaco, Lee Shaw, Roland Schauer, A. Marc, Jean‐Louis Goergen · 2003 · Biochimica et Biophysica Acta (BBA) - General Subjects
17. Treatment-induced antibodies to interleukin-2
    Otto Prümmer · 1997 · Biotherapy
18. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells
    Eugenio Carrasco-Marı́n, PAZ‐MIGUEL, LÓPEZ‐MATO, Carmen Alvarez-Domı́nguez, LEYVA‐COBIÁN · 1998 · Immunology
19. Three Generations of Immunoglobulin G Preparations for Clinical Use
    J. P. McCue, R. H. Hein, Robert A. Tenold · 1986 · Clinical Infectious Diseases
20. Comparative Study of Biosynthetic Human Growth Hormone Immunogenicity in Growth Hormone Deficient Children
    Catherine Rougeot, P.M. Marchand, FERNAND DRAY, F Girard, J C Job, M Pierson, C Ponté, PIERRE E. ROCHICCIOLI, R Rappaport · 2008 · Hormone Research
21. Growth Hormone Antibodies Formation in Patients Treated with Recombinant Human Growth Hormone
    Ghasem Ahangari, Mohammadreza Ostadali, A. Rabani, Juliet Rashidian, Mohammad Hossein Sanati, M R Zarindast · 2004 · International Journal of Immunopathology and Pharmacology
22. Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor
    Douglas G. McNeel, Kathy Schiffman, Mary Lenora Disis · 1999 · Blood
23. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: Evidence from a mouse model
    Shawn Babiuk, Danuta M. Skowronski, Gaston De Serres, Kent T. HayGlass, Robert C. Brunham, Lorne A. Babiuk · 2003 · Journal of Medical Virology
24. Roferon (rIFN-α 2a ) Is More Immunogenic Than Intron A (rIFN-α 2b ) in Patients with Chronic Myelogenous Leukemia
    Peter von Wussow, R. Hehlmann, T. Hochhaus, Detlef Jakschies, Klaus‐Ulrich Nolte, Otto Prümmer, H. Ansari, Joerg Hasford, Hermann Heimpel, Helmut Deicher · 1994 · Journal of Interferon Research
25. Immunogenicity of Therapeutic Proteins
    Suzanne Hermeling, Daan J.A. Crommelin, Huub Schellekens, Wim Jiskoot · 2010 · Pharmaceutical Sciences Encyclopedia
26. Asparagine deamidation: a regulatory hourglass
    Steven Jay Weintraub · 2004 · Mechanisms of Ageing and Development
27. Reversed-phase chromatography of interleukin-2 muteins
    Michael G. Kunitani, Pamela Hirtzer, Deborah Johnson, Robert Halenbeck, Albert Boosman, Kirston E. Koths · 1986 · Journal of Chromatography A
28. Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins
    Ilya Mukovozov, Thomas F. Sabljic, Gonzalo Hortelano, Frederick A. Ofosu · 2008 · Thrombosis and Haemostasis
29. The Rebif® New Formulation Story
    Amer Jaber, Reinoud J. Driebergen, Gavin Giovannoni, Huub Schellekens, James Simsarian, Michele Antonelli · 2007 · Drugs in R&D
30. RECOMBINANT HUMAN IL-2 IS CYTOTOXIC TO OLIGODENDROCYTES AFTER IN VITRO SELF AGGREGATION
    Laura Curatolo, Barbara Valsasina, Carla Caccia, G.L. Raimondi, G. Orsini, Angelo Bianchetti · 1997 · Cytokine
31. Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia A Mice
    Aaron Peng, Puneet Gaitonde, Matthew P. Kosloski, Razvan D. Miclea, Prashant Varma, Sathy V. Balu‐Iyer · 2009 · Journal of Pharmaceutical Sciences
32. Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge
    Ralph Smalling, MaryAnn Foote, Graham Molineux, Steven J. Swanson, Steve Elliott · 2004 · Biotechnology annual review
33. Isolation and Characterization of a Monomethioninesulfoxide Variant of Interferon α-2b
    Gerry Gitlin, Anthony Tsarbopoulos, Suman T. Patel, Wasyl Sydor, Birendra N. Pramanik, Sheila Jacobs, Louis Westreich, Stanley Mittelman, James N. Bausch · 1996 · Pharmaceutical Research
34. Nonclinical development of biopharmaceuticals
    Andreas Baumann · 2009 · Drug Discovery Today
35. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309
    Kearkiat Praditpornsilpa, Pawinee Kupatawintu, W. Mongkonsritagoon, O. Supasyndh, Saengsuree Jootar, T. Intarakumthornchai, Cholatip Pongskul, Wisit Prasithsirikul, Bunlusak Achavanuntakul, P. Ruangkarnchanasetr et al. · 2008 · Nephrology Dialysis Transplantation
36. Pharmacy considerations for the use of IGIV therapy
    Sachin R. Shah · 2005 · American Journal of Health-System Pharmacy
37. Monoclonal antibodies to human growth hormone can distinguish between pituitary and genetically engineered forms
    Roger Aston, Lesley Cooper, Andy Holder, Juraj Iványi, Mike Preece · 1985 · Molecular Immunology
38. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders
    Susan M. Richards · 2002 · Clinical and Applied Immunology Reviews
39. Structure of unfolded and refolded recombinant derived [Ala125]Interleukin 2
    Tsutomu Arakawa, T. Boone, Janice M. Davis, William C. Kenney · 1986 · Biochemistry
40. Correlation of rFVIII Inactivation with Aggregation in Solution
    Wei Wang, Drew N. Kelner · 2003 · Pharmaceutical Research
41. mAb therapeutic products and risk management
    Janice M. Reichert · 2010 · mAbs
42. Computational design of protein therapeutics
    Inseong Hwang, Sheldon Park · 2008 · Drug Discovery Today Technologies
43. Comparison of Antigenicity of Hoechst 21PH Insulin Using Either Implantable Intraperitoneal Pump or Subcutaneous External Pump Infusion in Type 1 Diabetic Patients
    N. Jeandidier, Sylvie Boullu, Marie-Sophie Busch-Brafin, G. Chabrier, Rémy Sapin, F Gasser, M. Pinget · 2002 · Diabetes Care
44. Adverse reactions to drug formulation agents; a handbook of excipients
    1990 · International Journal of Biochemistry
45. Incidence of GM-CSF Antibodies in Cancer Patients Receiving GM-CSF for Immunostimulation
    Gustav Jörgen Ullenhag, Chris Bird, Peter Ragnhammar, Jan‐Erik Frödin, Karin Strigård, A. Österborg, Robin Thorpe, Håkan Mellstedt, Meenu Wadhwa · 2001 · Clinical Immunology
46. Long Term Safety and Efficacy of Intraperitoneal Insulin Infusion by Means of Implantable Pumps
    M. Pinget, N. Jeandidier · 1998 · Hormone and Metabolic Research
47. Immunogenicity of xenopeptide hormone therapies
    Catherine A. Schnabel, Samuel Edwin Fineberg, Dennis Dong Hwan Kim · 2006 · Peptides
48. Opportunities and limitations of mouse models humanized for HLA class II antigens
    Birgit Maria Reipert, Katharina Nora Steinitz, Pauline M. van Helden, Sabine Unterthurner, M. SCHUSTER, Rafi Uddin Ahmad, Josenato Ilas, H. P. Schwarz · 2009 · Journal of Thrombosis and Haemostasis
49. Development of Anti‐hGH Antibodies during Therapy with Authentic Human Growth Hormone
    Knut E. A. Lundin, L. BERGER, Fred Blomberg, Patrick Wilton · 1991 · Acta Paediatrica
50. Three human interferon‐α2 subvariants disclose structural and functional differences
    Alexander von Gabain, Erik Lundgren, Monica OHLSSON, Erik Holmgren, Staffan JOSEPHSSON, Şefik Ş. Alkan · 1990 · European Journal of Biochemistry
51. Diabetes therapy trials with inhaled insulin
    Samuel Edwin Fineberg · 2006 · Expert Opinion on Investigational Drugs
52. Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects.
    PETER KONTSEK, Hana Liptáková, Eva Kontseková · 1999 · PubMed
53. Platform Technology for Developing Purification Processes
    Michel H. M. Eppink, Rick Schreurs, Anke Gijsen, Kees Verhoeven · 2009 · Socio-Environmental Systems Modeling
54. Interferon-α 2 Produced by Normal Human Leukocytes Is Predominantly Interferon-α 2b
    Mario DiPaola, TERESA SMITH, K. FERENCZ-BIRO, Mei‐June Liao, Douglas Testa · 1994 · Journal of Interferon Research
55. Circulating Molecular Variants of Growth Hormone in Childhood
    G Baumann, R J Winter, MELISSA A. SHAW · 1987 · Pediatric Research
56. Interleukin-2 self-association
    Jonathan D. Fleischmann, Deborah B. Wentworth, Frank Valencic, Anthony L. Imbembo, Karl A. Koehler · 1988 · Biochemical and Biophysical Research Communications
57. Recombinant Factor VIII SQ- Inactivation Kinetics in Aqueous Solution and the Influence of Disaccharides and Sugar Alcohols
    Angelica Fatouros, Thomas Österberg, Marianne Mikaelsson · 1997 · Pharmaceutical Research
58. FDA balks at Myozyme scale-up
    George S Mack · 2008 · Nature Biotechnology
59. Delivery of interleukin 2 for immunotherapy
    David R. Kaplan · 1994 · Journal of Chromatography B Biomedical Sciences and Applications
60. Differences between natural and recombinant interleukin-2 revealed by gel electrophoresis and capillary electrophoresis
    Joseph Knüver-Hopf, H. Mohr · 1995 · Journal of Chromatography A
61. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.
    Francesca Bellomi, Antonella Muto, Graziana Palmieri, Chiara Focaccetti, Caterina Dianzani, Maurizio Mattei, Amer Jaber, Guido Antonelli · 2007 · PubMed
62. Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma
    Ronald M. Bukowski, James Young, Gary E. Goodman, Frederick J. Meyers, Brian F. Issell, James S. Sergi, Denise McLain, G. Fyfe, James Harold Finke · 1993 · Investigational New Drugs
63. The immunogenicity of therapeutic cytokines.
    Danuta J. Herzyk · 2003 · PubMed
64. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants
    Paul James White, Frank Anastasopoulos, Jarrod E. Church, C.-Y. Kuo, Ben J. Boyd, Pascal Hickey, Linda Sze Tu, PJ Burns, Andrew M. Lew, William R. Heath et al. · 2008 · Vaccine
65. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-?1a: a double-blind, placebo-controlled comparison with the currently available formulation
    Chris Brearley, A. Jaber, M. Bertolino, Anthony Priestley, Michael Seiberling · 2007 · International Journal of Clinical Pharmacology and Therapeutics
66. Reaction to the paper: Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein–Surfactant Interactions
    Suzanne Hermeling, Wim Jiskoot, Daan J.A. Crommelin, Huub Schellekens · 2006 · Pharmaceutical Research
67. Factors affecting the expression of recombinant glycoproteins.
    Mercy Devasahayam · 2007 · PubMed
68. Low incidence of antibody formation due to long-term interferon-?2c treatment of cancer patients
    Gerhard G. Steinmann, B. G�d, Frank Rosenkaimer, Günther R. Adolf, G. Bidlingmaier, B. Fr�hbeis, Herbert R. Lamche, J. Lindner, Erik Patzelt, C. Schm�hling et al. · 1992 · Journal of Molecular Medicine
69. Phase separation analysis of recombinant interleukin 2
    Christoph A. Bergmann, Bonnie J. Landmeier, David R. Kaplan · 1991 · Molecular Immunology
70. Evidence for proteolytic cleavage of covalently bound protein a from a silica based extracorporeal immunoadsorbent and lack of relationship to treatment effects
    Joseph P. Balint, Frank R. Jones · 1995 · Transfusion Science
71. High Antigenicity of Intraperitoneal Insulin Infusion via Implantable Devices: Preliminary Rat Studies
    N. Jeandidier, Sandrine Boullu, E. Delatte, R Sapin, Jérôme Steibel, Pierre Meyer, C. Uhl, M. Pinget · 2001 · Hormone and Metabolic Research
72. Speculations on the immunogenicity of self proteins.
    Betty Diamond · 2003 · PubMed
73. Fatal intraoperative anaphylaxis after aprotinin administration.
    A. Prieto, A Villanueva, S Lain, Baeza Ml · 2008 · PubMed
74. Development and Shelf-Life Determination of Recombinant Interleukin-2 (Proleukin)
    John Geigert, Nicholas Solli, Peggy Woehleke, Sriram Vemuri · 1993 · Pharmaceutical biotechnology
75. Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties
    C.L. Ho, Yah-Luen Lin, Wan-Chen Chen, Raniero Rocchi, Tom Piek · 1998 · Toxicon
76. Native and recombinant interleukin-2, two functionally distinct molecules
    Maria C. Denis · 2003 · Molecular Immunology
77. Antigenicity of desamido-insulin and monocomponent insulin
    T. Kasama, Y Iwata, Kiichiro Oshiro, Michiko Uchida, Yutaka SAKAGUCHI, K. Namie, M. Sugiura · 1981 · Diabetologia
78. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    B Rup · 2003 · PubMed
79. Development and biochemical characterization of a double-virus-inactivated factor VIII preparation
    Susan J. Robinson, Horst Schwinn, Djuro Josić, I. Nur, Monika Stadler, Bal F, W. Gehringer, Rolf Schütz · 1995 · Blood Coagulation & Fibrinolysis
80. Latex allergens are not detectable in reconstituted smallpox vaccine or vaccine vial stoppers
    Gregory A. Poland, Inna G. Ovsyannikova, Richard T. Jones, John W. Yunginger · 2004 · Journal of Allergy and Clinical Immunology
81. Conformational Changes in pH2-Treated Human Interferon-Alpha 2 Detected with Monoclonal Antibodies
    O. Kúdela, Eva Kontseková, M Csabayová, KATARÍNA ZÁHOROVÁ, PETER KONTSEK · 1996 · Hybridoma
82. Untitled work
    2000 · 10.1002/1531-8249(200011)48:5
83. Untitled work
    Rhodes · 1997 · 10.1002/(sici)1097-4636(19971215)37:4